2 min read
Unlock the Secrets of Effective SD File Preparation for FDA Submissions
In today's world where digital transformation is reshaping industries, even the pharmaceutical sector is not immune to...
1 min read
Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954), a revenue-generating biotechnology company researching, developing and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce it has secured funding from Innovate UK to identify the quickest and most cost-effective route to market in both the UK and the US for Awakn’s lead program - proprietary ketamine-assisted therapy for treating AUD. Innovate UK is the UK’s national innovation agency which provided the funding in an initiative delivered jointly by CPI and ABHI.
Awakn’s activities will be delivered in collaboration with Veristat, a global Clinical Research Organization (CRO) that specialises in accelerating client therapies through the clinical development process into regulatory approval and commercialization. Veristat supported marketing applications for 12% of all US Food and Drug Administration (FDA) Novel Drug Approvals in 2021.
2 min read
Sep 20, 2023 Veristat Blog
In today's world where digital transformation is reshaping industries, even the pharmaceutical sector is not immune to...
10 min read
Sep 13, 2023 Veristat Blog
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US...